Looks like overcompensation to me. It was reasonable to think they'd have to raise cash periodically as most clinical stage bios do...Big deal. In the past, when i see a 20% abrupt plunge in the PPS with no real change in the potential earnings power of a clinical stage bio, it's been a fine time to buy as the PPS generally recovers.